Xbiotech | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.2.

EBIT: As of FY2025 Q3, the actual value is USD -7.474 M.

Financial Metrics by Segment

Segment Revenue

• No revenue reported for the three and nine months ended September 30, 2025, and 2024.

Operational Metrics

• Net Loss:
  • Three months ended September 30, 2025: - $6.0 million
  • Nine months ended September 30, 2025: - $18.6 million
  • Three months ended September 30, 2024: - $5.0 million
  • Nine months ended September 30, 2024: - $28.0 million
• Research and Development Expenses:
  • Three months ended September 30, 2025: $5.1 million
  • Nine months ended September 30, 2025: $22.0 million
  • Three months ended September 30, 2024: $7.1 million
  • Nine months ended September 30, 2024: $29.9 million
• General and Administrative Expenses:
  • Three months ended September 30, 2025: $1.0 million
  • Nine months ended September 30, 2025: $3.9 million
  • Three months ended September 30, 2024: $0.8 million
  • Nine months ended September 30, 2024: $3.8 million

Cash Flow

• Operating Cash Flow:
  • Nine months ended September 30, 2025: - $16.968 million
  • Nine months ended September 30, 2024: - $24.423 million
• Investing Cash Flow:
  • Nine months ended September 30, 2025: - $255 thousand
  • Nine months ended September 30, 2024: - $1.220 million
• Financing Cash Flow:
  • Nine months ended September 30, 2025: - $10.250 million
  • Nine months ended September 30, 2024: $10.167 million

Unique Metrics

• Share-Based Compensation:
  • Three months ended September 30, 2025: $24 thousand
  • Nine months ended September 30, 2025: $3.460 million
  • Three months ended September 30, 2024: $365 thousand
  • Nine months ended September 30, 2024: $1.125 million

Future Outlook and Strategy

• Core Business Focus: XBiotech Inc. expects to incur significant and increasing operating losses for the foreseeable future as it advances its drug candidates from discovery through preclinical testing and clinical trials. The company does not expect to generate any revenue in 2025 and will need to generate significant revenues to achieve or sustain profitability.
• Non-Core Business: The company is using its True Human™ antibody discovery technology to identify and develop new IL-1a targeting product candidates and has already brought one such candidate into clinical studies in oncology and rheumatology; and another unique anti-IL-1a antibody into a Phase I study in neurology.